Letters to the Editor

Randomized phase II trial of liposomal cytarabine and daunorubicin with or without pomalidomide in newly diagnosed acute myeloid leukemia myelodysplasia-related

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA; Augusta University Georgia Cancer Center, Augusta
Ohio State University Comprehensive Cancer Center, Columbus
University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill
University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill
Weill Cornell Medicine and The New York Presbyterian Hospital, New York
Ohio State University Comprehensive Cancer Center, Columbus
University of Kansas Cancer Center, Kansas City
University of Kansas Cancer Center, Kansas City
Atrium Wake Forest Baptist Comprehensive Cancer Center, Winston Salem
University of Cincinnati Comprehensive Cancer Center, Cincinnati
Emory University Winship Cancer Institute, Atlanta
University of Virginia Comprehensive Cancer Center, Charlottesville
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
Ohio State University Comprehensive Cancer Center, Columbus
Ohio State University Comprehensive Cancer Center, Columbus
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
National Cancer Institute, Bethesda
National Cancer Institute, Bethesda
Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC
Baylor College of Medicine, Houston
Johns Hopkins Sidney Kimmel Comprehensive Cancer Institute, Baltimore
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
Haematologica Early view Sep 24, 2026 https://doi.org/10.3324/haematol.2026.301466